two hours ago
A study conducted by researchers at the University of Turku in Finland revealed the possibility of using an (antigen) known as (CA125) to detect ovarian cancer.
The intended (antigen) is a glycoprotein present in the tissues of the female reproductive system, and by searching for it, ovarian cancer can be detected from a blood sample within 30 minutes, according to the study published in the latest issue of the journal “Biology Communications.”
“Compared with traditional diagnoses, the sensitivity of the CA125 test was 4.5 times higher in detecting ovarian cancer,” said doctoral candidate Sherif Bayoumi, the first author of the study, in a report published on the University of Turku website, Friday.
This test aims to expand screening to cover a larger group of patients to facilitate the initiation of more investigations and treatment options.
Dr. says. Kim Kim Peterson, from the University of Turku and co-researcher of the study: “The results obtained are very promising for early diagnosis of cancer, which is very important in treatment.”
Ovarian cancer occurs in women between the ages of 50-70 and affects approximately 1 in 70 women.
Ovarian cancer in the United States ranks second among the most common cancers that affect women, and the number of female deaths that result from it is greater than the number of deaths from any other gynecological cancer.